Published date:Dec 20 2024

Journal Title: West Kazakhstan Medical Journal

Issue title: West Kazakhstan Medical Journal: Volume 66 Issue 4

Pages:453 - 459

DOI: 10.18502/wkmj.v66i4.17780

Svetlana V Topolyanskayasshekshina@yahoo.comDepartment of Internal Medicine #2, First Moscow State Medical University (Sechenov University), Moscow

Rachina S.A.Department of Internal Medicine #2, First Moscow State Medical University (Sechenov University), Moscow

Karine A. LytkinaWar Veterans Hospital #3, Moscow

Georgiy G. MelkonyanWar Veterans Hospital #3, Moscow

Yulia A SavochkinaFederal State Budgetary Institution, Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical Biological Agency, Moscow

A single-center observational study was performed to evaluate the effectiveness and safety of the interleukin-6 inhibitor olokizumab in hospitalized adults with moderate COVID-19. This study enrolled 337 patients aged from 22 to 96 years old. After the administration of olokizumab, there was a significant reduction in body temperature, decrease in CRP, and an increase in the levels of blood cells. Revealed clinical improvement was seen in 69.7% of cases, 8.5% of patients showed deterioration in their condition and were transferred to the ICU, 13.6% died. Olokizumab was well tolerated except for slight elevation in live enzymes, such as aspartate transaminase and alanine transaminase.

Keywords: COVID-19, C-reactive protein, interleukin-6, olokizumab How

[1] WHO COVID-19 dashboard. https://data.who.int/dashboards/covid19/deaths (accessed 11 February, 2024)

[2] WHO COVID-19 dashboard. https://data.who.int/dashboards/covid19/cases?n=c (accessed 11 February, 2024)

[3] Adzic-Vukicevic T, Markovic D, Reljic A, Brkovic V. What did we learn about tocilizumab use against COVID-19? A single-center observational study from an intensive care unit in Serbia. Front. Med. 2023;10:1253135. doi: 10.3389/fmed.2023.1253135

[4] Mussini C, Cozzi-Lepri A, Meschiari M, et al. Do all critically ill patients with COVID-19 disease benefit from adding tocilizumab to glucocorticoids? A retrospective cohort study. Viruses. 2023; 15(2):294. doi: 10.3390/ v15020294

[5] van de Veerdonk, F.L., Giamarellos-Bourboulis, E., Pickkers, P., et al. A guide to immunotherapy for COVID-19. Nat Med. 2022;28(1):39-50. doi: 10.1038/s41591-021-01643-9

[6] Wei Q, Lin H, Wei RG, et al. Tocilizumab treatment for COVID-19 patients: a systematic review and meta-analysis. Infect Dis Poverty. 2021; 71. doi: 10.1186/s40249-021-00857-w

[7] Chen Cx, Hu F, Wei J, et al. Systematic review and meta-analysis of tocilizumab in persons with coronavirus disease-2019 (COVID-19). Leukemia. 2021;35:1661–1670. doi: 10.1038/s41375-021-01264-8

[8] Tavlueva E.V., Zernova E.V., Kutepova M.P., et al. Characteristics of olokizumab pharmacokinetics in patients with novel coronavirus infection COVID-19. Pharm Pharmacol. 2022;10(5):460-471 (In Russian). doi: 10.19163/2307- 9266-2022-10-5-460-471

[9] Ganyukova N.G., Likstanov M.I., Kosinova M.V., et al. Efficiency of IL-6 inhibitor (olokizumab) in suppressing inflammation in patients with moderate COVID-19 pneumonia. Fundam Clin Pharmacol. 2020;5(4):8-13 (In Russian). doi: 10.23946/2500-0764-2020-5-4-8-13

[10] Antonov, V.N., Ignatova, G.L., Pribytkova, O.V., et al. Experience of olokizumab use in COVID-19 patients. Ter Arch. 2020; 92(12): 148-154 (In Russian]. doi: 10.26442/00403660.2020.12.200522

[11] Fomina D.S., Andreev S.S., Andrenova G.V., et al. Efficacy of olokizumab in patients with mild or moderate COVID- 19 and risk factors of progression. Pul’monologiya. 2023; 33 (5): 623–632 (in Russian). doi: 10.18093/0869-0189- 2023-33-5-623-632

[12] 12. Tavlueva E.V., Markarov A.E., Petrushin M.A., et al. Olokizumab reduces the risks of death in hospitalized patients with moderate and severe COVID-19. Infektsionnye bolezni: novosti, mneniya, obuchenie. 2022; 11 (4): 8–18 (In Russian). doi: 10.33029/2305-3496-2022-11-4-8-18

[13] 13. Goma T.V., Kalyagin A.N., Ryzhkova O.V., Soloveva N.S. Efficacy of olocizumab in treatment of COVID-19 patients. Acta Biomed Sci. 2022; 7(5-2): 86-95 (In Russian). doi: 10.29413/ABS.2022-7.5-2.9

[14] Han, Q., Guo, M., Zheng, Y., et al. Current Evidence of Interleukin6 Signaling Inhibitors in Patients With COVID-19: A Systematic Review and Meta-Analysis. Front Pharmacol. 2020; 11: 615972. doi: 10.3389/fphar.2020.615972

[15] Sciascia, S., Aprà, F., Baffa, A., et al. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. Clin Exp Rheumatol. 2020; 38(3): 529-532.

[16] Guaraldi, G., Meschiari, M., Cozzi-Lepri, A., et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020;2(8):e474-e484. doi: 10.1016/S2665-9913(20)30173-9

[17] Sheikh A., McMenamin J., Taylor B., et al. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021; 397(10293): 2461-2462. doi: 10.1016/S0140-6736(21)01358-1